Migraine is a chronic and debilitating disorder characterized by recurrent attacks lasting four to 72 hours with multiple symptoms, including typically one-sided, pulsating headaches of moderate to severe pain intensity that are associated with nausea or vomiting, sound sensitivity and light sensitivity. Migraines can often be preceded by transient neurological warning symptoms, known as auras, which typically involve visual disturbances such as flashing lights but may also involve numbness or tingling in parts of the body. Migraine is both widespread and disabling.
The State of U.S. Health, 1990-2016 Study rates migraine as the fifth leading cause of years lived with disability. According to the Migraine Research Foundation, approximately 39 million individuals in the United States suffer from migraine attacks. Most sufferers experience migraine attacks once or twice per month and over 1.2 million emergency room visits are for acute migraine attacks. Of the 24 million diagnosed migraine patients, approximately 19 million are not on active treatment due to minimal to no benefit from prior treatment. Of the five million diagnosed and on prescription therapy, up to 79% of the patients are actively seeking better treatment options.
We are currently developing INP104, our upper nasal formulation of dihydroergotamine (DHE) administered using our proprietary POD technology for the treatment of acute migraine. DHE is widely used as part of a standard of care for treatment of migraines, in addition to the use of triptans, but has been limited by IV and injection delivery administered in physicians’ offices, migraine clinics and hospitals. We believe INP104 has the potential to be a best-in-class therapy for acute migraine. INP104 delivers DHE to the richly-vascularized upper nasal cavity, offering the potential for rapid and consistent response without injection.